Mentice Past Earnings Performance

Past criteria checks 0/6

Mentice's earnings have been declining at an average annual rate of -20.1%, while the Healthcare Services industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 14.1% per year.

Key information

-20.1%

Earnings growth rate

-17.7%

EPS growth rate

Healthcare Services Industry Growth	7.9%
Revenue growth rate	14.1%
Return on equity	-19.2%
Net Margin	-10.2%
Next Earnings Update	23 Jul 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Mentice makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:MN2 Revenue, expenses and earnings (SEK Millions)
Date	Revenue	Earnings	G+A Expenses
31 Mar 24	256	-26	223
31 Dec 23	275	-3	211
30 Sep 23	274	2	201
30 Jun 23	261	-6	199
31 Mar 23	230	-25	195
31 Dec 22	219	-31	192
30 Sep 22	215	-37	190
30 Jun 22	205	-36	177
31 Mar 22	207	-24	163
31 Dec 21	185	-29	153
30 Sep 21	165	-22	141
30 Jun 21	158	-15	132
31 Mar 21	136	-21	124
31 Dec 20	138	-13	122
30 Sep 20	152	-9	126
30 Jun 20	148	-17	135
31 Mar 20	156	-17	143
31 Dec 19	149	-21	143
30 Sep 19	154	-1	135
30 Jun 19	161	8	128
31 Mar 19	156	14	122
31 Dec 18	157	20	116
31 Dec 17	109	6	83

Quality Earnings: MN2 is currently unprofitable.

Growing Profit Margin: MN2 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MN2 is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.

Accelerating Growth: Unable to compare MN2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MN2 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-7.2%).

Return on Equity

High ROE: MN2 has a negative Return on Equity (-19.15%), as it is currently unprofitable.

Mentice Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)

Mentice AB (publ) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)

Third quarter 2023 earnings released

Mentice AB (publ) to Report First Half, 2024 Results on Jul 23, 2024

Second quarter 2023 earnings released: EPS: kr0.06 (vs kr0.72 loss in 2Q 2022)

Recent updates

Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)

Mentice AB (publ) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)

New minor risk - Market cap size

New major risk - Share price stability

Mentice Receives FDA 510(K) Clearance for Ankyras

Mentice Receives FDA 510(K) Clearance for Ankyras

Mentice AB (publ) (OM:MNTC) agreed to acquire All substantial assets of Biomodex from SIMARATO SAS for €0.2 million.

Director recently bought €71k worth of stock

Mentice (publ) Appoints Ulrika Drotz Voksepp as New Chief Financial Officer, Effective January 2, 2024

Mentice AB (Publ) Announces Board Appointments

Third quarter 2023 earnings released

Mentice AB (publ), Annual General Meeting, May 23, 2024

Mentice AB (publ) to Report First Half, 2024 Results on Jul 23, 2024

Mentice AB (Publ) Appoints of Jonatan Sjöström to Its Executive Management Group as Chief Operating Officer, Effective from September 14, 2023

New minor risk - Market cap size

Mentice AB (publ) Announces Chief Financial Officer Changes

Second quarter 2023 earnings released: EPS: kr0.06 (vs kr0.72 loss in 2Q 2022)

Insufficient new directors

Mentice AB (publ) Announces Resignation of Gunilla Andersson as Chief Financial Officer

Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)

Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)

Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.29 loss in 3Q 2021)

Mentice AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

Mentice AB (publ), Annual General Meeting, May 11, 2023

Second quarter 2022 earnings released: kr0.71 loss per share (vs kr0.22 loss in 2Q 2021)

Mentice AB (publ) to Report Q4, 2022 Results on Feb 09, 2023

Mentice AB (publ) (OM:MNTC) completed the acquisition of All assets of the Ankyras software suite from Galgo Medical SL.

Mentice AB (publ) (OM:MNTC) agreed to acquire All assets of the Ankyras software suite from Galgo Medical SL for €2.775 million.

First quarter 2022 earnings released: kr0.30 loss per share (vs kr0.50 loss in 1Q 2021)

High number of new directors

Mentice AB (publ) Announces Change of Chairman of Board, Effective December 30, 2022

High number of new directors

Mentice Appoints Jan Grund Pedersen as New Vice President of Strategic Alliances & Business Development

Mentice AB (publ) to Report Fiscal Year 2021 Results on Apr 06, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: kr0.29 loss per share (vs kr0.014 loss in 3Q 2020)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Chief Financial Officer Elisabet Lund has left the company

Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)

Less than half of directors are independent

Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.50 loss per share (vs kr0.21 loss in 1Q 2020)

New 90-day low: €7.52

Full year 2020 earnings released: kr0.54 loss per share (vs kr1.05 loss in FY 2019)

Revenue misses expectations

Mentice Announces Executive Appointments

Mentice AB (publ) to Report Fiscal Year 2020 Results on Feb 04, 2021

Third quarter 2020 earnings released: kr0.01 loss per share

Revenue misses expectations

Mentice AB (Publ) Announces Nomination Committee

New 90-day low: €7.00

Mentice AB (publ) (OM:MNTC) entered into agreement to acquire substantially all assets of EQIP, Inc. for $0.25 million.

Mentice AB (publ) (OM:MNTC) signed a definitive agreement to acquire Substantial All Assets of Vascular Simulations LLC for $6 million.

Mentice AB (publ) to Report Q2, 2020 Results on Aug 13, 2020

Mentice AB (publ) to Report Q3, 2020 Results on Nov 12, 2020

New 90-day high - €7.36

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies